⚡️🇺🇸#INCY #отчетность
Incyte - Q1 Non-GAAP EPS of $0.67 beats by $0.03; GAAP EPS of $0.24 misses by $0.17.
Revenue of $605M (+6.4% Y/Y) misses by $55.72M.
Jakafi (ruxolitinib) revenues of $466M (+1% Y/Y) vs. consensus of $516.5M.
#прогноз Reaffirms full year guidance of Jakafi (ruxolitinib) revenues of $2.125-$2.20 billion.
Incyte - Q1 Non-GAAP EPS of $0.67 beats by $0.03; GAAP EPS of $0.24 misses by $0.17.
Revenue of $605M (+6.4% Y/Y) misses by $55.72M.
Jakafi (ruxolitinib) revenues of $466M (+1% Y/Y) vs. consensus of $516.5M.
#прогноз Reaffirms full year guidance of Jakafi (ruxolitinib) revenues of $2.125-$2.20 billion.